Analyst Research
| Report Title | Price |
|---|---|
|
Provider: S&P Capital IQ Quantitative Report
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cytokinetics, Inc. Raises FY 2012 Revenue Guidance
Cytokinetics, Inc. updated financial guidance for fiscal 2012 which incorporates the estimated costs associated with CY 4026. The Company anticipates revenue will be in the range of $5.0 to $7.0 million.
Latest Developments for Cytokinetics Inc
- Cytokinetics, Inc. Announces $60 Million Financing
- Cytokinetics, Inc. Announces Publication Of Phase II Evidence Of Effect Study Of CK-2017357 In Journal Amyotrophic
- Cytokinetics, Inc. Reaffirms FY 2012 Revenue Guidance-Conference Call
- Cytokinetics, Inc. Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 In Patients With Amyotrophic Lateral Sclerosis
Latest Key Developments in Biotechnology
- Share this
- Link this
- Digg this
Follow Reuters